DUBLIN--(BUSINESS WIRE)--The "Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2018, outlays comprehensive information on the Calcitonin Gene Related Peptide (CGRP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
It also reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development with respective active and dormant or discontinued projects.
Companies Featured
- Alder BioPharmaceuticals Inc.
- Eli Lilly and Co.
- Serometrix LLC
- Teva Pharmaceutical Industries Ltd.
Scope
- The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP)
- The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics
Featured News & Press Releases
- Alder BioPharmaceuticals Presents New One-Year Data for Eptinezumab from PROMISE 1 Phase 3 Trial Demonstrating Long-Term Efficacy in Episodic Migraine
- Alder BioPharmaceuticals Presents New Six-Month Data for Eptinezumab Demonstrating Improvement in Efficacy in PROMISE 2 Phase 3 Trial for Chronic Migraine
- Teva to Present New Fremanezumab Data, Including Long-Term Data, at the American Headache Society's 60th Annual Scientific Meeting
- Lilly Emgality (galcanezumab-gnlm) Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed BOTOX (onabotulinumtoxinA)
- Alder BioPharmaceuticals to Present New Data Further Highlighting Eptinezumab's Efficacy Profile for Migraine Prevention at American Headache Society Meeting
- and more...
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5cv7xs/calcitonin_gene?w=4
